Shanghai Bao Pharmaceuticals files HKEX next-day disclosure return reporting share repurchase

• Shanghai Bao Pharmaceuticals repurchased 63,100 H shares on July 28, 2026 for treasury, no shares cancelled.
• Buyback price range HKD 18.25 to HKD 18.82; aggregate consideration HKD 1.19 million.
• Issued shares excluding treasury fell to 152,594,350; treasury shares rose to 1,732,900.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260728-12259019), on July 28, 2026, and is solely responsible for the information contained therein.